BRCA1 and Inherited cancer-predisposing syndrome: The wider availability and reducing cost of NGS-based multi-gene panel testing has led to increasing use of multi-gene panel testing for hereditary cancer syndrome in the clinic, in turn resulting in the rise in diagnosing cancer syndromes originating from other moderate to high penetrance cancer predisposition genes outside the mismatch repair and BRCA1/2 genes.